MIT BRAIN TUMOUR PATENT CASE – ECJ – GERMANY
December 1st, 2005
BY KEITH NUTHALLTHE MASSACHUSETTS Institute of Technology (MIT) has won crucial support at the European Court of Justice (ECJ) in securing a supplementary protection certificate in Germany for brain tumour drug Gliadel. The MIT is appealing against the German Patent and Trade Mark Office's blocking this protection, because the drug's key active ingredient carmustine has been long established and Gliadel's technological advance is combining it with biodegradable polifeprosan that regulates the release of this therapeutic material, rather than attacking tumours ...
Full access to this article can be arranged with permission from the client that first ordered it. Please contact us to request access. Entries are uploaded to our archive at least one year after being published by a client – free access is restricted to International News Services journalists for background research only. The article date indicates when copy was filed to a client, not when posted to this archive. Upon client requests, International News Services will remove such articles from the archive or not upload them in the first place. They are included to demonstrate the breadth of topics undertaken by the agency and also to help promote clients’ coverage.